Treatment of Suspected MRSA Wound Infection
For a suspected MRSA wound infection, the treatment approach depends critically on whether the wound is purulent or non-purulent, and whether the patient requires hospitalization—with incision and drainage being the cornerstone of therapy for any drainable abscess, followed by empirical antibiotic coverage based on infection severity.
Outpatient Management
Simple Abscess or Boil
- Incision and drainage alone is the primary treatment and may be sufficient for simple, uncomplicated abscesses 1
- Antibiotics should be added if any of the following are present:
- Severe or extensive disease (multiple sites)
- Rapid progression with surrounding cellulitis
- Signs of systemic illness (fever, tachycardia)
- Comorbidities or immunosuppression
- Extremes of age
- Difficult-to-drain locations (face, hand, genitalia)
- Lack of response to drainage alone 1
Purulent Cellulitis (with drainage but no drainable abscess)
Empirical MRSA coverage is recommended pending culture results 1
Oral antibiotic options for 5-10 days:
- Clindamycin (A-II evidence)
- Trimethoprim-sulfamethoxazole (TMP-SMX) (A-II evidence)
- Doxycycline or minocycline (A-II evidence)
- Linezolid (A-II evidence)
Coverage for β-hemolytic streptococci is likely unnecessary in purulent infections 1
Non-Purulent Cellulitis
- Primary coverage should target β-hemolytic streptococci with a β-lactam antibiotic 1
- Add MRSA coverage if:
- Patient fails to respond to β-lactam therapy
- Signs of systemic toxicity are present 1
If dual coverage needed: Use clindamycin alone OR combine TMP-SMX/tetracycline with amoxicillin OR use linezolid alone 1
Hospitalized Patients with Complicated Wound Infections
For deeper soft-tissue infections, surgical/traumatic wounds, major abscesses, or infected ulcers/burns, empirical IV MRSA therapy is indicated alongside surgical debridement 1
IV antibiotic options for 7-14 days:
- Vancomycin (A-I evidence)
- Linezolid 600 mg twice daily PO or IV (A-I evidence)
- Daptomycin 4 mg/kg/dose IV once daily (A-I evidence)
- Telavancin 10 mg/kg/dose IV once daily (A-I evidence)
- Clindamycin 600 mg IV or PO three times daily (A-III evidence)
Recent network meta-analysis data suggest that linezolid may have superior clinical success rates compared to vancomycin for MRSA skin and soft tissue infections, though it carries higher adverse reaction rates 2. The combination of vancomycin with rifampin also showed improved outcomes, though rifampin monotherapy or routine adjunctive use is not recommended 1, 2.
Critical Management Points
Culture Collection
Obtain cultures from purulent wounds in the following situations 1:
- Any patient receiving antibiotic therapy
- Severe local infection or systemic illness
- Inadequate response to initial treatment
- Concern for outbreak or cluster
Avoid These Pitfalls
- Do not use rifampin as single agent or routine adjunctive therapy for skin infections 1
- Do not use tetracyclines in children <8 years old 1
- For non-purulent cellulitis in hospitalized patients, consider starting with cefazolin and switching to MRSA-active therapy only if no clinical response 1
Pediatric Modifications
- Mupirocin 2% topical ointment for minor infections (impetigo, secondarily infected lesions) 1
- For hospitalized children: Vancomycin is first-line (A-II)
- Clindamycin 10-13 mg/kg/dose IV every 6-8 hours is an alternative if local resistance <10% and patient is stable 1
- Linezolid: 600 mg twice daily for >12 years; 10 mg/kg every 8 hours for <12 years 1
Duration of Therapy
- Outpatient infections: 5-10 days (individualize based on clinical response) 1
- Hospitalized complicated infections: 7-14 days (individualize based on clinical response) 1
- Response should be evident within the first few days; if not, reassess diagnosis and antibiotic choice 3
The evidence strongly supports that surgical source control through incision and drainage is non-negotiable for drainable collections, with antibiotics serving as adjunctive therapy rather than primary treatment for localized abscesses 1.